Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
NCT00883896
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
195
Enrollment
INDUSTRY
Sponsor class
Conditions
Rheumatoid Arthritis
Interventions
OTHER:
Placebo
DRUG:
ILV-094
DRUG:
ILV-094
OTHER:
Placebo
DRUG:
ILV-094
Sponsor
Pfizer